Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia

NCT07432100 is registered in ClinicalTrials.gov with Mingfeng Zhao as lead sponsor.

NCT NCT07432100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07432100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia
Lead sponsor
Mingfeng Zhao
Phase
Phase 1
Overall status
Not yet recruiting
Start date
February 28, 2026
Completion date
December 12, 2028
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, chimeric antigen receptor t-cell, universal cll1 car-t